Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response.
The ability of prostate-specific antigen (PSA) to predict long-term cure after cryotherapy for localized prostate cancer is not known because experience with this treatment modality is limited; however, it appears that a PSA value of 0.5 ng/mL or less at 6 months or longer after cryotherapy is associated with a high probability of a negative post-treatment biopsy (greater than 95%). An undetectable PSA (less than 0.1 ng/mL) 3 months after the procedure is associated with a likelihood of a negative biopsy at 6 months and low, stable PSA levels up to 2 years.